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Aim/hypothesis IFNα, a cytokine expressed in human islets from type 1 diabetes patients, 
plays a key role in the pathogenesis of diabetes by up-regulating inflammation, endoplasmic 
reticulum (ER) stress and MHC class I overexpression, three hallmarks of islet histology in 
early type 1 diabetes. We presently tested whether expression of these mediators of beta cell 
loss is reversible upon IFNα withdrawal or IFNα pathway inhibition. 
Methods IFNα-induced MHC class I overexpression, ER stress and inflammation were 
evaluated by flow cytometry, immunofluorescence and RT-PCR in human EndoC-βH1 cells 
or human islets exposed to IFNα with or without the presence of JAK inhibitors. Protein 
expression was evaluated by western blot.  
Results IFNα-induced expression of inflammatory and ER stress markers returned to baseline 
after 24-48 h following cytokine removal. By contrast, MHC class I overexpression at the cell 
surface persisted for at least 7 days. Treatment with JAK inhibitors, added together with 
IFNα, prevented MHC class I overexpression, but when added 24 h after IFNα exposure 
these inhibitors failed to accelerate MHC class I return to baseline.  
Conclusion/interpretation IFNα mediates a long-lasting and preferential MHC class I 
overexpression in human beta cells, which is not affected by the subsequent addition of JAK 
inhibitors. These observations suggest that IFNα-stimulated long-lasting MHC class I 
expression may amplify beta cell antigen presentation during the early phases of type 1 
diabetes and that IFNα inhibitors might need to be used at very early stages of the disease to 
be effective.	
Keywords: Type 1 diabetes, IFNα, MHC class I, pancreatic beta cells, pancreatic islets, JAK 
inhibitors 
Abbreviations: 
BIP  Binding immunoglobulin protein 
CHOP  C/EBP homologous protein 
CHX  Cycloheximide 
CXCL10 C-X-C motif chemokine ligand 10
ER Endoplasmic reticulum
HO  Hoechst 33342
JAK  Janus kinase
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MX1  MX dynamin like GTPase 1 
STAT  Signal transducer and activator of transcription 
TYK2  Tyrosine kinase 2 
 
Introduction 
The overexpression of major histocompatibility complex (MHC) class I in pancreatic islets, 
probably secondary to local interferon-α (IFNα) production, is a key feature in the 
pathogenesis of type 1 diabetes [1, 2]. The primary function of MHC class I is to transport 
intracellular (endogenous or viral) peptides to the cell surface, where they are presented and 
recognized by cytotoxic CD8+ T cells, leading to killing of the antigen-expressing cells or, in 
some cases, to development of tolerance [3]. 
We have recently shown that IFNα induces MHC class I overexpression, inflammation and 
endoplasmic reticulum (ER) stress in human beta cells. These effects are mediated via 
activation of the Janus kinase (JAK-TYK2)/STAT pathway [4], with a key role for the type 1 
diabetes candidate gene TYK2, whose encoded protein phosphorylates and activates STATs 
[4, 5]. JAK/TYK2 inhibitors have been recently approved for the treatment of other 
autoimmune diseases, such as rheumatoid arthritis [6]. 
To evaluate the possibility of targeting the IFNα pathway for the treatment of type 1 diabetes, 
we presently tested whether the effects of IFNα are reversible upon cytokine withdrawal or 
IFNα pathway inhibition. We present evidence that IFNα promotes a specific and long-
lasting MHC class I overexpression in human beta cells. Moreover, while exposure of human 
beta cells to IFNα in the presence of the JAK inhibitors ruxolitinib and cerdulatinib prevents 
IFNα-induced expression of MHC class I and other stress markers, these inhibitors fail to 
accelerate MHC class I return to baseline if added 24 h after IFNα exposure. These results 
suggest that IFNα-stimulated long-lasting MHC class I expression may contribute to 
prolonged beta cell antigen presentation during early steps of type 1 diabetes. 
Methods 
Culture of human EndoC-βH1 cells and human islets, and cell treatments 
The human beta cell line EndoC-βH1 (kindly provided by Dr. R. Scharfmann, University of 
Paris, France) was cultured in Matrigel-fibronectin-coated plates as described [4]. These cells 
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are free from mycoplasma infection, as evaluated by MycoAlert Mycoplasma Detection kit 
(Lonza, Basel, Switzerland). 
Isolation of human islets from 3 non-diabetic organ donors (ESM Table 1) was performed in 
accordance with the local Ethical Committee in Pisa, Italy. After arrival in Brussels, islets 
were dispersed and cultured as in [4]. All experiments shown with EndoC-βH1 cells or 
human islet cells (indicated as “n” in the figures) refer to independent biological data (i.e 
using EndoC-βH1 cells from different passages or human islets from different donors). 
Where indicated, cells were treated with human IFNα (PeproTech Inc., Rocky Hill, NJ) 20 or 
1000 U/ml [4]. Cells were treated with ruxolitinib (kindly provided by Calibr, CA, USA), 
cerdulatinib (Selleckchem, Germany), Bayer-18 (Synkinase, UK), or cycloheximide (Sigma-
Aldrich, Germany) as indicated.  
Flow cytometry and immunofluorescence 
EndoC-βH1 cells were plated in 24-well plates (150,0000 cells/well). After treatment, cells 
were incubated with mouse anti-MHC class I antibody (W6/32) (1:1000) for 2 h and 
subsequently with a BV421-conjugated secondary antibody before analyses by flow 
cytometry (FacsCanto; BD Biosciences, CA, USA) as described [4]. The cellular populations 
were separated based on size and granularity and further analysed for BV421 fluorescence. 
Immunofluorescence was performed as previously described [4], using mouse anti-MHC 
class I (W6/32) (1:1000) and guinea pig anti-insulin antibodies (1:250), Hoechst (HO) and 
Alexa Fluor-conjugated secondary antibodies (ESM Table 2).  
mRNA extraction and real-time PCR 
EndoC-βH1 cells were plated in 96-well plates (45,000 cells/well). After treatment, poly(A)+ 
mRNA was isolated using the Dynabeads mRNA DIRECT kit (Invitrogen) following the 
manufacturer’s instructions, and reverse transcribed as described [5]. Quantification by real-
time PCR was carried out using SYBR Green. Gene expression values were corrected by the 
housekeeping gene β-actin, as its expression is not affected by the conditions used in this 
study [5]. The primers used are listed in ESM Table 3. 
Statistical analysis 
Data are expressed as means ± SEM. A significant difference between experimental 
conditions was assessed by one-way or two-ways ANOVA followed by paired or unpaired t 
test with Bonferroni correction using the GraphPad Prism program. Results with p<0.05 were 
considered statistically significant. 
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Results 
IFNα, tested at two concentrations (1000 and 20 U/ml), strongly induced the expression of 
MHC class I (Fig. 1a-c and ESM Fig. 1a-c), the chemokine C-X-C motif chemokine ligand 
10 (CXCL10), the antiviral MX dynamin like GTPase 1 (MX1) (Fig. 1d, f and ESM Fig. 1d, 
e), and the ER stress markers C/EBP homologous protein (CHOP) and the binding 
immunoglobulin protein BIP (Fig. 1g, h and ESM Fig. 1f, g) in EndoC-βH1 cells. When 
IFNα was removed from the medium (“wash”) and the cells cultured in its absence for 
subsequent periods of 24 h to 7 days, MHC class I protein and, to a less extent, mRNA 
remained overexpressed for at least 7 days (Fig. 1a-c and ESM Fig. 1a-c), while the 
inflammatory markers CXCL10 and MX1 (Fig. 1d, f and ESM Fig. 1d, e) and the ER stress 
markers CHOP and BIP (Fig. 1g h and ESM Fig. 1f, g) started to decrease already by 24-48 
h. CXCL10 secretion to the medium, as measured by ELISA, also decreased by 24 h, 
returning to near basal (control) levels by 72 h (Fig. 1e). Importantly, IFNα-mediated MHC 
class I overexpression also persisted for at least 7 days in dispersed human islets (Fig. 2).  
 
Pre-treatment with the JAK inhibitors ruxolitinib and cerdulatinib prevented IFNα-induced 
HLA-ABC, CXCL10, MX1 and CHOP expression in a dose-dependent manner (ESM Fig. 2a-
h). These JAK inhibitors also prevented IFNα-induced CXCL10 secretion (ESM Fig. 2m). 
On the other hand, the “TYK2 inhibitor” Bayer-18 showed no effect on IFNα-induced gene 
expression (ESM Fig. 2i-l) and therefore was not further used. We also evaluated the effect of 
Bayer-18 in two other cell lines (HeLa and PANC-1) and again fail to observe inhibition of 
IFNα-induced MHC class I expression (data not shown). This unexpected observation 
emphasizes the need to validate in human beta cells and other cell types the different 
JAK/TYK2 inhibitors, ahead of future clinical trials. Despite their ability to prevent IFNα 
signalling, ruxolitinib and cerdulatinib did not accelerate MHC class I return to baseline when 
added after IFNα stimulation and its subsequent removal (ESM Fig. 3), suggesting that 
continuous IFNα signalling is not necessary for the long-lasting MHC class I overexpression 
observed in human beta cells. 
The protein synthesis inhibitor cycloheximide (CHX) significantly reduced MHC class I 
basal expression, while it did not affect IFNα-induced MHC class I expression over 16 h 
(ESM Fig. 4a, b). After 48 h in the continuous presence of CHX, IFNα-induced MHC class I 
overexpression remained unchanged and similar to non-CHX-treated cells (data not shown). 
These results suggest that IFNα both induces a marked MHC class I overexpression and 
6	
	
stabilizes the protein at the cell surface. Of note, CHX decreased β-catenin, β-actin, and BIP 
expression over time, confirming the efficiency of the treatment (ESM Fig. 4c, d).  
 
Discussion 
MHC class I overexpression is induced by proinflammatory cytokines, such as IFNα [2] and 
IFNγ [1], in human islets from type 1 diabetes patients. Besides inducing MHC class I 
expression, IFNα also induces human beta cell ER stress and production of chemokines [4], 
suggesting that this cytokine is a key player in the early stages of human type 1 diabetes and 
in the transition between innate and adaptive immune responses. We presently show that 
MHC class I remains overexpressed at the cell surface of beta cells even after 7 days of IFNα 
withdrawal, while markers of inflammation and ER stress rapidly return to baseline. When 
added together with IFNα, JAK inhibitors prevent these effects of the cytokine, but fail to 
accelerate the return to baseline if added 24 h after IFNα stimulation, suggesting that 
following beta cell exposure to the cytokine a continuous IFNα stimulation is not required for 
the persistent MHC class I expression at the cell surface. These findings rise the possibility 
that IFNα-stimulated MHC class I expression, together with other inflammatory mediators, 
will amplify beta cell antigen presentation during the early phases of type 1 diabetes and 
suggest that IFNα inhibitors might need to be used at very early stages of the disease to be 
effective. These findings raise also the issue on the best “window of opportunity” for an 
eventual use of JAK inhibitors as therapeutic agents in T1D. Recent studies indicate that 
expression of a type I IFN response signature in circulating cells actually precedes the 
detection of autoantibodies in children at risk for T1D [7, 8]. If detection of this signature is 
shown to have accurate predictive power and becomes part of the routine follow up for at risk 
children, its presence could be a good moment for intervention. Alternatively, 
normoglycaemic children positive for two or more autoantibodies could be considered, but it 
remains to be seen whether this will allow reversion of the putative local manifestations of 
activated innate/adaptive immunity.  
It is noteworthy that IFNα not only induces a massive overexpression of MHC class I but also 
seems to stabilize the protein at the cell surface of human beta cells (present data). In line 
with this, IFNγ induces both MHC class I expression and stability at the cell surface in 
murine myeloblast cells [9]. Ligand-free MHC molecules that reach the cell surface are 
rapidly degraded [10]. Thus, the presently observed long-lasting maintenance of MHC class I 
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expression at the human beta cell surface may be due to the parallel abundance of antigenic 
peptides generated in response to IFNα [11].  
What is the “biological meaning” of this long-lasting IFNα-induced MHC class I mRNA and 
protein expression in human beta cells, while other markers of beta cell stress – including 
chemokines – return to baseline already by 24 h? A constant expression of MHC class I 
complexes in the absence of co-stimulation might be a mechanism to induce immune 
tolerance rather than immunity [12]. It is thus conceivable that, following a short local innate 
immune response (for instance, following brief “danger signals” provided by a limited viral 
infection or exposure to nuclear debris from dying cells), the transitory IFNα stimulation will 
lead to prolonged MHC class I expression in the absence of parallel chemokine production or 
expression of co-stimulatory molecules, favouring the switch from immunity to immune 
tolerance. Another possibility is that the prolonged expression of MHC class I on the target 
cells will enable the immune system to efficiently detect and delete beta cells expressing 
foreign peptides (e.g. cells with low or early viral infection), thus preventing a second wave 
of infection. It is conceivable that the role for the observed prolonged MHC class I expression 
in beta cells is context dependent, and additional studies are required to clarify this issue.  
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Figure legends 
Figure 1. IFNα induces a specific and long-lasting MHC class I overexpression in 
EndoC-βH1 cells. 
EndoC-βH1 cells were left untreated (NT, black bars) or treated with IFNα (white bars; 1000 
U/ml) for 24 h. Afterwards, culture medium was changed to remove IFNα (“wash”) and the 
cells were cultured in the absence of IFNα for 24 h, 48 h, 72 h, 96 h, or 7 days (grey bars). (a, 
b) MHC class I protein expression was measured by FACS. The percentage of positive cells 
(a) and the mean of fluorescence intensity (expressed as fold-change in MFI relative to the 
untreated sample) (b) were quantified. Results are means ± SEM of 4-18 independent 
measurements per condition (n=18 for NT and IFNα, and n=4-6 for the other conditions). 
mRNA expression of HLA-ABC (c), CXCL10 (d), MX1 (f), CHOP (g) and BIP (h) was 
analysed by RT-PCR, normalised by β-actin and then by the highest value of each experiment 
considered as 1. Results are means ± SEM of 3-9 independent experiments (i.e. using cells 
from different passages) per condition (n=9 for NT and IFNα, and n=3-5 for the other 
conditions). CXCL10 protein secretion to the supernatant was determined by ELISA (e). 
Results are means ± SEM of 6 independent experiments. *p<0.05, **p<0.01 and ***p<0.001 
vs NT; †p<0.05, ††p<0.01 and †††p<0.001 vs IFNα, as indicated by bars (one way ANOVA). 
 
Figure 2. IFNα induces a long-lasting MHC class I overexpression in dispersed human 
islets. 
Dispersed human islets were left untreated or treated with IFNα (1000 U/ml) for 24 h. 
Afterwards, culture medium was changed to remove IFNα (“wash”) and the cells were 
cultured in the absence of IFNα for 48 h or 7 days. Immunocytochemistry (ICC) analysis of 
MHC class I (red), insulin (green) and HO (blue) was performed to analyse MHC class I 
expression in 3 independent human islet preparations (magnification x40). 
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ESM methods 
Study design 
For each recovery experiment (flow cytometry and gene expression), a condition “wash” - 
where cells were transitorily exposed to IFNα, followed by medium change (“wash”) - was 
compared to a negative control condition (not treated) and a positive control condition (IFNα 
24 h; cells studied at the end of this period). We first evaluated the impact of “wash 24 h” 
(i.e. cells studied 24 h after removal of IFNα) on MHC class I expression and, observing the 
surprising finding that MHC class I remained overexpressed, progressively increased the 
period of incubation without IFNα to 48 h, 72 h, 96 h and 7 days until a significant difference 
with the positive control was observed. At least 3 independent experiments with respective 
controls (i.e. biologically different samples) were performed for each time point evaluated, 
therefore increasing the “n” for the controls. Since the control values were similar in the 
different experiments, they are presented as pooled results in the different figures. 
ELISA 
The CXCL10 release to the supernatant (by 45,000 cells/200 µl; culture time as indicated in 
the legend for the figures) was determined by enzyme-linked immunosorbent assay 
(Quantikine ELISA kit, R&D Systems, Minneapolis, MN, USA).  
Western blot analysis 
EndoC-βH1 cells were plated in 96-well plates (45,000 cells/well). After treatment, cells 
were washed with cold PBS and lysed using Laemmli buffer. Immunoblot analyses were 
performed using antibodies against BIP, β-catenin (both at 1:1000 dilution), and β-actin 
(1:5000). Horseradish peroxidase-coupled antibodies were used as secondary antibodies 
(1:5000). Immunoreactive bands were detected as described using the SuperSignal West 
Femto chemiluminescent substrate (Thermo Scientific) and ChemiDoc XRS+ (Bio-Rad), and 
quantified with the Image Studio Lite v5.2 software (LI-COR Biosciences). A list of the 
antibodies used herein are described in ESM Table 2. 
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ESM Table 1. Characteristics of the human donors used in the present study. 
Date of the islet 
preparation 
Age 
(years) Gender 
BMI 
(kg/m2) Cause of death 
Proportion of 
beta cells in the 
preparation (%) 
01.04.2017 78 M 23.4 Trauma 43 
23.05.2017 63 F 26 Cerebral 
haemorrhage 
45 
17.07.2017 79 F 20 Trauma 50 
 
M (male); F (female); BMI (body mass index) 
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ESM Table 2. Antibodies used in the present study. 
 
Antibody Company Reference Dilution MW, kDa 
BIP Cell Signalling, Danvers, MA, USA 3183 1:1000 ~78 
β-actin Cell Signalling, Danvers, MA, USA 4967 1:5000 ~45 
β-catenin Santa Cruz, Dallas, Texas, USA Sc-133239 1:1000 ~92 
Insulin DAKO, California, USA A0564 1:250 - 
MHC Class I 
(W6/32) 
Enzo Life Sciences, 
Lausen, Switzerland ALX-805-711 1:1000 - 
Peroxidase-
conjugated donkey 
anti-rabbit IgG 
Jackson 
ImmunoResearch 
Laboratories, Wes 
Grove, PA, USA 
715-136-150 1:5000 - 
Peroxidase-
conjugated donkey 
anti-mouse IgG 
Jackson 
ImmunoResearch 
Laboratories, Wes 
Grove, PA, USA 
711-036-154 1:5000 - 
BV421 goat anti-
mouse Ig BD Biosciences, USA 563846 1:1000 - 
Alexa Fluor 488 
goat anti-GP IgG Life technologies, USA A11073 1:200 - 
Alexa Fluor 568 
rabbit anti-mouse 
IgG 
Life technologies, USA A11061 1:200 - 
 
Antibodies have been previously validated and used by our group [1]. 
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ESM Table 3. Primers used in the present study. 
 
 Forward Reverse 
Sequence (5’-3’) Sequence (5’-3’) 
Human β-
actin CTGTACGCCAACACAGTGCT GCTCAGGAGGAGCAATGATC 
Human 
HLA-ABC GAGAACGGGAAGGAGACGC CATCTCAGGGTGAGGGGCT 
Human 
CXCL10 GTGGCATTCAAGGAGTACCTC GCCTTCGATTCTGGATTCAG 
Human 
CHOP Qiagen QuantiTect primer, cat# QT00082278 
Human 
BIP Qiagen QuantiTect primer, cat# QT00096404 
Human 
MX1 AGACAGGACCATCGGAATCT GTAACCCTTCTTCAGGTGGAAC 
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ESM Figure 1. A low dose of IFNα  also induces a long-lasting MHC class I expression 
in EndoC-βH1 cells. 
EndoC-βH1 cells were left untreated (NT, black bars) or treated with IFNα (white bars; 20 
U/ml) for 24 h. The medium was then changed to remove IFNα (“wash”) and the cells were 
cultured in the absence of IFNα for subsequent periods of 24 h, 48 h, 72 h, 96 h or 7 days 
(grey bars). (a, b) MHC class I protein expression was measured by FACS. The percentage of 
positive cells (a) and the mean of fluorescence intensity (expressed as fold-change in MFI 
relative to the untreated sample) (b) were quantified. Results are means ± SEM of 3-11 
independent measurements per condition (n=11 for NT and IFNα, and n=3-5 for the other 
conditions). mRNA expression of HLA-ABC (c), CXCL10 (d), MX1 (e), CHOP (f) and BIP 
(g) was analysed by RT-PCR, normalised by β-actin and then by the highest value of each 
experiment considered as 1. Results are means ± SEM of 2-8 independent measurements per 
condition (n=8 for NT and IFNα, and n=2-4 for the other conditions).  **p<0.01 and 
***p<0.001 vs NT; †p<0.05, ††p<0.01 and †††p<0.001 vs IFNα, as indicated by bars (one way 
ANOVA). 
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ESM Figure 2. JAK inhibitors block IFNα-induced gene expression in EndoC-βH1 cells 
in a dose-dependent manner. 
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EndoC-βH1 cells were left untreated or pre-treated with the indicated JAK inhibitor 
concentrations (100, 500, 1000 or 4000 nmol/l) for 2 h. Afterwards, cells were left untreated 
(black bars), treated with IFNα alone (white bars; 1000 U/ml) or with IFNα in presence of 
ruxolitinib (a-d, m), cerdulatinib (e-h, m) or Bayer-18 (i-l) (grey scale bars) for 24 h. mRNA 
expression of HLA-ABC (a, e, i), CXCL10 (b, f, j), MX1 (c, g, k) and CHOP (d, h, l) was 
analysed by RT-PCR, normalised by β-actin and then by the highest value of each experiment 
considered as 1. Results are means ± SEM of 3-9 independent experiments. CXCL10 protein 
secretion to the supernatant was determined by ELISA (e) after IFNα exposure for 24h in the 
presence or not of ruxolitinib (4000 nmol/l, light grey bar) or cerdulatinib (4000 nmol/l, dark 
grey bar). Results are means ± SEM of 3 independent experiments. *p<0.05, **p<0.01 and 
***p<0.001 vs NT; ††p<0.01 and †††p<0.001 vs IFNα, as indicated by bars (one way 
ANOVA). 
 
 
ESM Figure 3. Addition of JAK inhibitors after IFNα treatment does not accelerate 
MHC class I return to baseline. 
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EndoC-βH1 cells were left untreated (NT, black bars) or treated with IFNα (white bars; 1000 
U/ml) for 24 h. Afterwards, culture medium was changed to remove IFNα and the cells were 
cultured in the absence of inhibitor (dark-grey bars; IFNα wash) or in the presence of 
ruxolitinib (light-grey bars) or cerdulatinib (stripped bars) (4 µmol/l) for 24 h, 48 h, 72 h or 7 
days. (a, b) MHC class I protein expression was measured by FACS. The percentage of 
positive cells (a) and the mean of fluorescence intensity (b) were quantified. Results are 
means ± SEM of 3-20 independent experiments (n=20 for NT and IFNα, and n=3-5 for the 
other conditions). (c) mRNA expression of HLA-ABC was analysed by RT-PCR, normalised 
by β-actin and then by the highest value of each experiment considered as 1. Results are 
means ± SEM of 3-15 independent experiments (n=15 for NT and IFNα, and n=3-6 for the 
other conditions). **p<0.01 and ***p<0.001 vs NT; †p<0.05 vs IFNα wash and the same 
time point, as indicated by a bar (two ways ANOVA). 
 
 
 
ESM Figure 4. IFNα stabilizes MHC class I proteins at the cell surface. 
(a-b) EndoC-βH1 cells were left untreated (NT) or treated with IFNα (1000 U/ml) for 24 h. 
Afterwards, the medium was changed to remove IFNα and the cells were left untreated or 
treated with cycloheximide (CHX, 5 µg/ml) for 16 h. (a, b) MHC class I protein expression 
was measured by FACS. The percentage of positive cells (a) and the mean of fluorescence 
intensity (b) were quantified. Results are means ± SEM of 4 independent experiments. (c, d) 
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EndoC-βH1 cells were treated with cycloheximide (CHX, 5 µg/ml) for 24 h or 48 h. Protein 
expression was measured by western blot and representative images of 3-4 independent 
experiments are shown (c). Densitometry results are shown for β-actin (black squares), β-
catenin (black circles) and BIP (open circles) (d). Values were normalised by the value at 
time 0 of each protein considered as 1. *p<0.05, **p<0.01 and ***p<0.001 vs “no CHX” and 
the same pre-treatment (a, b) (paired t test) or vs time 0 (d) (one way ANOVA). 
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